Nerve pain is so difficult to treat because it does not behave like ordinary pain. While a broken bone or a pulled muscle sends a clear, proportional signal that fades as tissue heals, neuropathic pain involves damaged or misfiring nerves that generate their own false alarms — firing without cause, amplifying minor sensations into agony, and rewiring the spinal cord and brain to perpetuate suffering long after any original injury has resolved. Roughly 70% of neuropathic pain patients do not achieve even partial relief with currently available treatments, and opioid painkillers, the drugs most people associate with serious pain management, have less than a 20% efficacy rate against nerve pain specifically. For the estimated 7-10% of the global population living with neuropathic pain, the standard medical toolkit has been failing for decades.
But the landscape is shifting. In January 2025, the FDA approved Journavx (suzetrigine), the first genuinely new class of pain medication since 1999 — a drug that blocks pain signals at their source without any addiction risk. Beyond that single approval, a wave of experimental therapies targeting cannabinoid receptors, nerve growth factors, and sodium channel subtypes are advancing through clinical trials. The International Association for the Study of Pain has designated 2026 as a Global Year focused on pain research, and analysts project that five to seven additional breakthrough pain therapies could reach patients by 2028. This article examines why conventional treatments fall short, what the best current evidence says works, how Journavx represents a genuine turning point, and which emerging therapies hold the most promise for people living with chronic nerve pain — including those whose neuropathy is connected to neurological conditions like dementia.
Table of Contents
- Why Is Nerve Pain So Much Harder to Treat Than Other Types of Pain?
- What Does the Best Evidence Say Actually Works Right Now?
- Journavx — The First New Pain Drug Class in Over 25 Years
- Emerging Therapies — What Else Is in the Pipeline?
- The Risks and Limitations That Patients Should Understand
- What This Means for People Living With Dementia and Neurological Conditions
- Looking Ahead — Why the Next Few Years Matter
- Conclusion
- Frequently Asked Questions
Why Is Nerve Pain So Much Harder to Treat Than Other Types of Pain?
Most pain medications were designed for what researchers call nociceptive pain — the straightforward kind caused by tissue damage. Anti-inflammatories reduce swelling. Opioids dampen pain signals in the brain. These approaches work because the pain system is functioning normally; it is simply reporting real damage. Neuropathic pain is fundamentally different. The nerves themselves are broken, and the pain they produce is not a symptom of ongoing injury but a disease of the signaling system itself. Multiple mechanisms operate simultaneously: ectopic nerve activity generates spontaneous pain signals, peripheral and central sensitization amplify those signals, ion channel alterations change how nerves fire, and the balance between excitatory and inhibitory signaling in the spinal cord tips toward perpetual activation. Treating one mechanism often leaves the others untouched. This complexity explains why a single drug rarely provides adequate relief.
Consider a patient with diabetic peripheral neuropathy, one of the most common forms of nerve pain. Their damaged nerves may be spontaneously firing due to sodium channel dysfunction, while their spinal cord has simultaneously become sensitized to amplify whatever signals arrive. Gabapentin might partially calm the spinal cord sensitization, but it does nothing about the misfiring peripheral nerves. An opioid might blunt the brain’s perception of incoming signals, but opioid receptors are poorly distributed along the neuropathic pain pathway, which is why their efficacy rate is so low. Compared to treating a sprained ankle — where ibuprofen addresses both the inflammation and the resulting pain — treating nerve pain is like trying to fix a short circuit by turning down the volume on the alarm. The side-effect burden compounds the problem. The current first-line medications — gabapentin, pregabalin, tricyclic antidepressants, and SNRIs — all cause significant dizziness, drowsiness, and nausea. For older adults, particularly those with cognitive concerns or early dementia, these sedating side effects can be dangerous, increasing fall risk and accelerating confusion. Doctors frequently cannot escalate to effective doses because patients cannot tolerate the side effects, leaving millions of people on medications that are technically “prescribed for” their condition but functionally inadequate.
What Does the Best Evidence Say Actually Works Right Now?
A major Lancet Neurology systematic review published in 2025 examined 313 trials involving nearly 50,000 patients and confirmed that tricyclic antidepressants, gabapentin, pregabalin, and SNRIs remain the most effective first-line drug treatments for neuropathic pain. That may sound discouraging — these are the same drugs that have been used for years — but the review’s value lies in what it clarified about relative effectiveness and in establishing a rigorous evidence base that can guide treatment sequencing. Tricyclic antidepressants like amitriptyline, for instance, showed consistent benefit but come with cardiac risks that make them unsuitable for many older patients. SNRIs like duloxetine may be better tolerated in that population but are somewhat less effective on average. Beyond medications, two non-drug approaches have shown meaningful results. High-frequency repetitive transcranial magnetic stimulation (rTMS) demonstrates 30-45% pain reduction in responsive patients.
This noninvasive brain stimulation technique targets the motor cortex and appears to recalibrate how the brain processes pain signals. However, it requires repeated sessions at a specialized clinic, insurance coverage is inconsistent, and not all patients respond. Ketamine infusions offer 25-45% pain reduction during and immediately after treatment, but the effects are often short-lived, and the infusions must be administered in medical settings with monitoring. Neither approach is a cure; both are tools that can meaningfully reduce suffering for some patients while researchers work toward better options. The critical limitation to understand is that “most effective available” does not mean “effective enough.” Even the best-performing drugs in that Lancet review left the majority of patients with significant residual pain. If you or a family member is being told that gabapentin or pregabalin is “the treatment” for nerve pain and it is not providing adequate relief, that experience is not unusual — it reflects a genuine gap in what medicine can currently offer, not a failure on the patient’s part. Asking about combination therapy, non-drug options, or emerging treatments is entirely reasonable.
Journavx — The First New Pain Drug Class in Over 25 Years
On January 30, 2025, the FDA approved Journavx (suzetrigine), a 50 mg oral tablet manufactured by Vertex Pharmaceuticals, for moderate to severe acute pain in adults. What makes this drug significant is not just that it works — it is how it works. Journavx selectively blocks NaV1.8 sodium channels in the peripheral nervous system, stopping pain signals before they ever reach the brain. NaV1.8 channels are found predominantly on pain-sensing nerve fibers, which means the drug targets the pain pathway with unusual precision. A Northwestern University pain expert called the approval “a major breakthrough,” and for once, that language is not hyperbole. The most consequential feature of Journavx is what it does not do. It carries no addiction potential. It does not produce euphoria, sedation, or respiratory depression — the effects that make opioids both dangerous and prone to misuse.
For the millions of patients who need something stronger than over-the-counter painkillers but for whom opioids pose unacceptable risks, including older adults with cognitive decline, this represents a genuinely new option. The side-effect profile in clinical trials was significantly better than opioids, though as with any new medication, long-term real-world data will take time to accumulate. There is one important caveat: Journavx is currently approved only for acute pain, not for chronic neuropathic conditions. For the nerve pain community, the next milestone matters enormously. Vertex Pharmaceuticals has Phase 3 trials underway for diabetic peripheral neuropathy, with results expected in 2026-2027. The company also plans to evaluate suzetrigine for painful lumbosacral radiculopathy — sciatica, in plain language. If those trials succeed, the drug’s impact could expand dramatically. But until then, patients with chronic nerve pain cannot yet access Journavx for their condition through standard prescribing, and it would be premature to treat it as a guaranteed solution for long-term neuropathic pain.
Emerging Therapies — What Else Is in the Pipeline?
Several fundamentally different approaches to nerve pain are working their way through clinical development, and their diversity is part of what makes the current moment genuinely hopeful. Pilavapadin, an AAK1 inhibitor, is positioned as potentially the first oral, non-opioid therapy approved specifically for neuropathic pain in over 20 years. Unlike Journavx, which blocks sodium channels, pilavapadin works through an entirely different mechanism involving adapter-associated kinase 1, a protein involved in how nerve cells process and recycle signaling receptors. If it succeeds, doctors would have two mechanistically distinct non-opioid options — and in a field where single drugs rarely provide full relief, the ability to combine different mechanisms is crucial. Researchers at Northeastern University, publishing in September 2025, developed new compounds that act as dualsteric modulators of CB1 and CB2 cannabinoid receptors. These compounds harness the body’s own endocannabinoid pain control system to reduce nerve pain, inflammation, and swelling — without the psychoactive effects of cannabis.
This matters because many patients have found partial relief from cannabis products but cannot tolerate the cognitive effects, a concern that is especially acute for people with neurological conditions. A targeted pharmaceutical that activates the same pathways without impairing thinking could be particularly valuable for the dementia care community. The tradeoffs between these approaches are worth understanding. Sodium channel blockers like Journavx are highly targeted but may not address central sensitization. Cannabinoid receptor modulators work on both peripheral and central pathways but face a longer regulatory road due to their relationship to cannabis. Anti-nerve growth factor antibodies like tanezumab tackle pain at the molecular source of nerve sensitization but have raised safety concerns about joint damage, which is why approval would require a risk management program and would carry projected annual costs of $13,000-$20,000. No single therapy is likely to become a universal solution, and the most effective future treatment plans will probably involve combining approaches that target different parts of the pain pathway.
The Risks and Limitations That Patients Should Understand
The wave of promising research should not obscure several hard realities. First, timeline optimism can be cruel to people in pain today. Phase 3 trial results expected in 2026-2027 means that even if everything goes perfectly, widespread availability of Journavx for chronic nerve pain is likely years away. Pilavapadin and cannabinoid receptor modulators are earlier in development. The projection that five to seven breakthrough therapies could reach patients by 2028 comes from industry analysis and represents a best-case scenario — drug development timelines frequently slip. Second, new does not always mean better for every patient. Resiniferatoxin (RTX), a potent capsaicin analog, has shown remarkable results in preclinical studies, completely alleviating mechanical and thermal hyperalgesia when applied to uninjured nerves adjacent to damaged ones.
But it works by essentially destroying the pain-sensing nerve endings it contacts — a permanent intervention that cannot be reversed if side effects emerge. For some patients with severe, localized neuropathic pain, that tradeoff might be worthwhile. For others, particularly those whose pain is widespread or whose condition might improve, irreversible nerve ablation is a serious gamble. Patients should be wary of any treatment presented as universally beneficial without discussion of its specific limitations. Third, access and cost barriers will shape who benefits from new therapies. Even if tanezumab receives approval, annual costs of $13,000-$20,000 will put it out of reach for many patients without comprehensive insurance coverage. Treatments like rTMS and ketamine infusions, while available now, require repeated clinic visits and are often not covered by insurance. The gap between “a treatment exists” and “a treatment is accessible to the people who need it” remains one of the most persistent problems in pain medicine.
What This Means for People Living With Dementia and Neurological Conditions
Nerve pain and dementia intersect in ways that are both common and commonly overlooked. Diabetes, one of the leading causes of peripheral neuropathy, is also a significant risk factor for dementia. Patients with Parkinson’s disease frequently develop neuropathic pain as the disease damages autonomic nerves. And people with dementia are often unable to clearly describe their pain, leading to chronic undertreatment — agitation and behavioral changes that are actually unrecognized pain responses get treated with sedatives or antipsychotics rather than pain management.
The development of non-sedating pain medications like Journavx is particularly relevant here. Current first-line neuropathic pain drugs — gabapentin, pregabalin, tricyclic antidepressants — all carry sedation and cognitive impairment as major side effects, exactly the effects most dangerous in a dementia population. A pain drug that works without crossing into the brain or affecting cognition could meaningfully improve quality of life for people who have been caught between untreated pain and medication-induced confusion. Caregivers should discuss emerging options with neurologists and pain specialists, particularly as chronic pain trial results for suzetrigine become available.
Looking Ahead — Why the Next Few Years Matter
The International Association for the Study of Pain designated 2026 as a Global Year focused specifically on pain research advances, a signal that the field’s momentum is being recognized at the highest institutional levels. The convergence of multiple mechanistically distinct therapies — sodium channel blockers, cannabinoid modulators, nerve growth factor inhibitors, AAK1 inhibitors — entering late-stage development simultaneously has not happened before in pain medicine. An estimated five to seven additional breakthrough therapies targeting fundamentally different mechanisms are projected to reach patients by 2028.
None of this guarantees a revolution, and the history of pain research is littered with promising compounds that failed in late-stage trials. But the current pipeline is deeper and more diverse than at any previous point. For the first time in decades, there is a credible path toward treating nerve pain with the same kind of targeted, mechanism-based approach that has transformed fields like oncology and cardiology. Patients and caregivers who have been told “we have tried everything” should know that “everything” is about to include options that did not exist even two years ago.
Conclusion
Nerve pain resists conventional treatment because it involves a broken signaling system, not simply a damage report — multiple simultaneous mechanisms generate and amplify pain that no single existing drug adequately addresses. The 2025 Lancet Neurology review of 313 trials confirmed that current first-line medications help some patients but leave the majority with significant unrelieved pain. The FDA approval of Journavx marks the first genuinely new mechanism of action in pain medication since 1999, and its lack of addiction potential and favorable side-effect profile represent a meaningful advance, even though chronic nerve pain indications are still being studied.
For patients and caregivers navigating nerve pain today, the practical takeaway is threefold: first, inadequate relief from current medications is the norm, not a personal failure, and pushing for combination therapy or specialist referral is warranted. Second, ask specifically about emerging options — ongoing clinical trials for suzetrigine in diabetic neuropathy and sciatica may offer access before formal approval. Third, stay attentive to the pipeline. The next two to three years will bring clinical trial results for multiple fundamentally new approaches, and the treatment landscape for nerve pain in 2028 will look substantially different from what it is today.
Frequently Asked Questions
Is Journavx (suzetrigine) available for chronic nerve pain right now?
Not yet. Journavx was FDA-approved in January 2025 for moderate to severe acute pain only. Phase 3 clinical trials for diabetic peripheral neuropathy are underway, with results expected in 2026-2027. Patients interested in accessing it sooner may want to ask their doctor about clinical trial enrollment.
Why don’t opioids work well for nerve pain?
Opioids have less than a 20% efficacy rate for neuropathic pain because opioid receptors are poorly positioned along the neuropathic pain pathway. Nerve pain involves misfiring signals from damaged nerves and spinal cord sensitization — mechanisms that opioids were not designed to address. They also carry addiction risks that make long-term use problematic.
Are there any non-drug treatments for nerve pain that actually work?
High-frequency repetitive transcranial magnetic stimulation (rTMS) has shown 30-45% pain reduction in responsive patients, and ketamine infusions can provide 25-45% pain reduction, though effects are often temporary. Both require clinical settings and may not be covered by insurance. Physical therapy, cognitive behavioral therapy, and neuromodulation devices can also play a supporting role.
Is nerve pain medication safe for people with dementia?
Current first-line medications like gabapentin and pregabalin cause sedation and cognitive impairment, which are particularly risky for people with dementia. Newer drugs like Journavx work in the peripheral nervous system without sedating the brain, potentially offering a safer option — though chronic pain approval is still pending. Any medication decisions should involve both a neurologist and pain specialist.
How many people with nerve pain actually get adequate treatment?
Approximately 70% of neuropathic pain patients do not achieve even partial relief with currently available treatments. Neuropathic pain affects an estimated 7-10% of the global population, meaning tens of millions of people worldwide are living with inadequately treated nerve pain.
What new nerve pain treatments are coming in the next few years?
Several fundamentally different approaches are in development: pilavapadin (an AAK1 inhibitor), dualsteric cannabinoid receptor modulators from Northeastern University, resiniferatoxin (a capsaicin analog for targeted nerve ablation), and tanezumab (an anti-nerve growth factor antibody). Industry analysts project five to seven breakthrough pain therapies could reach patients by 2028.
